Zobrazeno 1 - 10
of 5 852
pro vyhledávání: '"hormone‐sensitive"'
Autor:
Marta Garcia de Herreros, Natalia Jiménez, Leonardo Rodríguez-Carunchio, Eva Lillo, Mercedes Marín-Aguilera, Laura Ferrer-Mileo, Caterina Aversa, Samuel García-Esteve, Joan Padrosa, Isabel Trias, Laia Fernández-Mañas, Albert Font, Isabel Chirivella, Mariona Figols, Miguel Ángel Climent, Aleix Prat, Òscar Reig, Begoña Mellado
Publikováno v:
European Urology Open Science, Vol 70, Iss , Pp 86-90 (2024)
Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with treatment resistance, worse survival, and aggressive variants of prostate cancer (AVPC). We previously developed and validated a signature reflecting low TSG exp
Externí odkaz:
https://doaj.org/article/bbfdf6631a7e44cc9c6c254191b07fed
Autor:
Mario Hassi Roman, Kinga Mate, Pedro De Pablos-Rodriguez, Álvaro Zamora Horcajada, Ana Guijarro Cascales, Ángeles Sanchís Bonet, Antoni Vilaseca, Darío Vázquez-Martul Pazos, Estefanía Linares Espinós, Jesús Muñoz Rodríguez, José Manuel de la Morena Gallego, José Ramón Alemán, Juan Gómez Rivas, Luigi Formisano, Maria J. Juan Fita, Marc Costa Planells, Mario Domínguez Esteban, Meritxell Pérez Márquez, Miguel García Sanz, Nagore García Expósito, Natalia Picola, Pol Servian Vives, Raquel Sopeña Sutil, Miguel A. Climent Durán, Miguel Ramírez Backhaus
Publikováno v:
European Urology Open Science, Vol 70, Iss , Pp 58-63 (2024)
Background and objective: The depth of the prostate-specific antigen (PSA) decline after androgen receptor pathway inhibitor (ARPI) treatment combined with androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (m
Externí odkaz:
https://doaj.org/article/0fc7ebd364174fe89c2487f7f9fb39f3
Autor:
Junichi Ikeda, Hisanori Taniguchi, Hiroki Takayama, Yuki Masuo, Takahiro Nakamoto, Katsunori Uchida, Hidefumi Kinoshita
Publikováno v:
IJU Case Reports, Vol 7, Iss 6, Pp 459-462 (2024)
Introduction Neuroendocrine prostate cancer is an aggressive histological subtype of prostate cancer with a poor prognosis. Neuroendocrine prostate cancer is traditionally treated with cisplatin‐based chemotherapy, similar to that used in treating
Externí odkaz:
https://doaj.org/article/6d799244b3224637bb13ef0c326b5499
Autor:
Mike Wenzel, Carolin Siech, Benedikt Hoeh, Florestan Koll, Clara Humke, Derya Tilki, Thomas Steuber, Markus Graefen, Séverine Banek, Luis A. Kluth, Felix K.H. Chun, Philipp Mandel
Publikováno v:
European Urology Open Science, Vol 66, Iss , Pp 46-54 (2024)
Background and objective: With approval of novel systemic therapies within the past decade for metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate cancer, patients may receive several therapy lines. However, the use of thes
Externí odkaz:
https://doaj.org/article/1758ca2edc274ae3ab0b726c095d034f
Publikováno v:
Zhongguo aizheng zazhi, Vol 34, Iss 7, Pp 680-685 (2024)
Background and purpose: Both prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and circulating tumor DNA (ctDNA) sequencing outcomes serve as references for therapeutic decision-making in hormone-sens
Externí odkaz:
https://doaj.org/article/44adfd68680149a7accbaa87c58758e9
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Inflammation plays a pivotal role in the progression of prostate cancer (PCa). Several immune-inflammatory indices, including neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), lymphocyte to monoc
Externí odkaz:
https://doaj.org/article/c12b65c89ac24d5e89627e71f255e933
Autor:
Viktoria Schütz, Christopher-Leo Nessler, Anette Duensing, Stefanie Zschäbitz, Dirk Jäger, Jürgen Debus, Markus Hohenfellner, Stefan Duensing
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Background and objectivesThe standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT), novel antihormonal therapies (NHT) and/or chemotherapy. Patients with newly diagnosed ol
Externí odkaz:
https://doaj.org/article/55526ddb1a4544fcb376b9317bf51d81
Autor:
Ang Li, Kai Shen, Yiyi Ji, Weiwei Zhang, Bo Liu, Ruopeng Su, Xiang Zhou, Liang Dong, Yinjie Zhu, Baijun Dong, Jiahua Pan, Qi Wang, Wei Xue
Publikováno v:
Annals of Medicine, Vol 56, Iss 1 (2024)
Introduction This retrospective study aimed to evaluate the prognostic value of [18F]FDG parameters in patients with visceral and bone metastatic hormone-sensitive prostate cancer (mHSPC).Patients and methods This analysis included the mHSPC patients
Externí odkaz:
https://doaj.org/article/ecd61103a0574d6297af0fd81c9f0184
Autor:
Motohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, Hiroji Uemura, Atsushi Mizokami, Masashi Kato, Hisashi Matsushima, Takeo Kosaka, Motonobu Nakamura, Satoshi Fukasawa, Matthew R. Smith, Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Haruka Kakiuchi, Masanao Akiyama, Rui Li, Iris Kuss, Heikki Joensuu, Hiroyoshi Suzuki
Publikováno v:
Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)
Abstract Background In the global ARASENS study (NCT02799602), darolutamide plus androgen‐deprivation therapy (ADT) and docetaxel significantly reduced risk of death by 32.5% versus placebo plus ADT and docetaxel (hazard ratio [HR] 0.68; 95% confid
Externí odkaz:
https://doaj.org/article/1058407c6e5d4f8494ab24581515bb95
Publikováno v:
Journal of Men's Health, Vol 20, Iss 6, Pp 1-7 (2024)
Androgen deprivation therapy (ADT) has long been the only treatment for metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, with the use of docetaxel chemotherapy and the emergence of various novel hormone therapy drugs, such as Ab
Externí odkaz:
https://doaj.org/article/6d1fc38fd99a40e5b4543dddd858bd3f